Notably, PDLIM2 is frequently repressed in lung tumors through both genetic loss and epigenetic silencing, with loss of heterozygosity and/or promoter methylation observed in over 90% of lung cancer patients [10]. This evidence concerns the gene PDLIM2 and lung carcinoma.